FLT3 and acute myeloid leukemia: These mutated cells exhibit greater resistance to FLT3i, such as quizartinib, compared to FLT3-ITD cells, resulting in relapse and poor patient prognosis, which is a representative mechanism of AML resistance observed clinically during quizartinib treatment [7, 54, 56].